Disease Management

866. Deputy Keira Keogh asked the Minister for Health for an update on her Department's engagement with parents of children who they suspect suffer from PANS-PANDAS; the measures her Department is taking to develop guidelines; and if she will make a statement on the matter. [53347/26]

278. Deputy Emer Currie asked the Minister for Health to outline Government policy on access to continuous glucose monitoring devices for people with type two diabetes; whether she will request a rapid health technology assessment to inform future eligibility and reimbursement; if so, the expected timeline for same; and if she will make a statement on the matter. [49946/26]

279. Deputy Emer Currie asked the Minister for Health having regard to her responsibility for national diabetes policy, the steps she is taking to ensure that the HSE publishes the outcome of the preferred sensor exercise, which was due in the first quarter of 2026; the revised publication date; and if she will make a statement on the matter. [49947/26]

309. Deputy Erin McGreehan asked the Minister for Health the current status of the health technology assessment and reimbursement decision for pluvicto (lutetium-177 PSMA therapy) for the treatment of metastatic castration-resistant prostate cancer; the timeline for a final determination; and if she will make a statement on the matter. [50111/26]

310. Deputy Erin McGreehan asked the Minister for Health the steps being taken to ensure Irish patients have timely and equitable access to innovative oncology treatments, including radioligand therapies such as pluvicto; and the way Ireland compares with other EU Member States in access to such treatments. [50112/26]

311. Deputy Erin McGreehan asked the Minister for Health the current capacity within the public health system to deliver radioligand therapies, including the availability of nuclear medicine facilities, trained personnel, and radiopharmacy supports; and the plans in place to expand this capacity. [50113/26]

312. Deputy Erin McGreehan asked the Minister for Health whether her Department has undertaken or commissioned any strategic review of Ireland's nuclear medicine and radiopharmacy infrastructure; and the actions planned to develop a sustainable, indigenous capability in this area. [50114/26]

313. Deputy Erin McGreehan asked the Minister for Health if consideration is being given to developing a national strategy for radiopharmaceutical production and usage, in light of increasing global demand and supply constraints; and if she will outline any engagement with industry, academia, or international partners on this issue. [50115/26]

314. Deputy Erin McGreehan asked the Minister for Health the level of capital and operational investment allocated to nuclear medicine and advanced cancer therapies over the past five years; and the projected investment over the next five years to support emerging treatments such as radioligand therapies. [50116/26]

315. Deputy Erin McGreehan asked the Minister for Health the current number of specialists in nuclear medicine, radiopharmacy, and medical physics in Ireland; the projected workforce requirements to support expansion in radioligand therapies; and the plans to address any identified gaps. [50117/26]

316. Deputy Erin McGreehan asked the Minister for Health the supports in place to enable Irish participation in international clinical trials involving radiopharmaceuticals and targeted radionuclide therapies; and the way in which Ireland can position itself as a hub for such research. [50118/26]

317. Deputy Erin McGreehan asked the Minister for Health the extent of engagement with patient advocacy organisations, including those representing prostate cancer patients, in relation to the reimbursement and provision of new treatments such as pluvicto. [50119/26]

318. Deputy Erin McGreehan asked the Minister for Health if she will support a dedicated session of the relevant Oireachtas Committee to examine the case for investment in nuclear medicine and radiopharmacy infrastructure, including emerging cancer therapies; and if officials from her Department would be available to attend. [50120/26]

924. Deputy Michael Lowry asked the Minister for Health the reasons Crohn's disease is not included among the conditions covered under the long-term illness scheme; whether consideration has been given to extending eligibility for a long-term illness card to persons living with Crohn's disease and other chronic lifelong conditions that require ongoing medication, treatment and monitoring; and if s…

494. Deputy Michael Cahill asked the Minister for Health to examine documents (details supplied) in relation to children who are suffering with long-Covid; and if she will make a statement on the matter. [48598/26]

499. Deputy Albert Dolan asked the Minister for Health if she will review the current list of conditions covered under the long-term illness scheme; if consideration is being given to the inclusion of Crohn’s disease and other inflammatory bowel diseases, in light of their chronic and lifelong nature and the ongoing medication requirements associated with their management; and if she will make a s…

517. Deputy David Cullinane asked the Minister for Health the estimated cost of implementing the rare disease action plan in full. [48666/26]

213. Deputy John Connolly asked the Minister for Health the services that are available for people diagnosed with dementia or Alzheimer’s disease in the Clifden area; the details of how these services can be accessed; and if she will make a statement on the matter. [44212/26]

2053. Deputy Ken O'Flynn asked the Minister for Health whether the proposed rare disease early-access framework will include formal eligibility criteria, maximum decision timelines, independent clinical oversight arrangements, and national equity safeguards; and if she will make a statement on the matter. [42490/26]

2054. Deputy Ken O'Flynn asked the Minister for Health whether her Department has conducted any estimate of the potential annual cost exposure associated with a rare disease early-access framework; and if she will make a statement on the matter. [42491/26]

2055. Deputy Ken O'Flynn asked the Minister for Health whether any ethical or legal review has been conducted regarding prioritisation criteria within the proposed early-access framework for rare diseases; and if she will make a statement on the matter. [42492/26]

2056. Deputy Ken O'Flynn asked the Minister for Health whether patient registries or national prevalence datasets will form part of the planned rare disease reimbursement reforms; and if she will make a statement on the matter. [42493/26]

2328. Deputy Ken O'Flynn asked the Minister for Health whether any national respiratory disease monitoring, surveillance, forecasting, winter-planning, population-health management or health-service demand forecasting system currently incorporates prescribing, reimbursement or utilisation data held by the Primary Care Reimbursement Service; if so, to identify each such system, the datasets used, t…

223. Deputy Shónagh Ní Raghallaigh asked the Minister for Health if genetic testing targeting diagnosis of those types of Ehlers Danlos syndrome identifiable by such tests will become available to the general population under the Rare Diseases Strategy 2025-2030; and if she will make a statement on the matter. [40446/26]

287. Deputy Ruairí Ó Murchú asked the Minister for Health if harm in rare disease pathways has been known at ministerial, departmental, and HSE service level for years; the reason the State has still not fully activated an independent national structure capable of preventing drift, ensuring policy cohesion, and delivering timely intervention instead of prolonged exposure to avoidable deterioration…